Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy

Preventive Cardiology
Kota J ReddyMisbah S Zaheer

Abstract

Lipoprotein-associated phospholipase A2 (Lp-PLA(2)) mass is a novel inflammatory biomarker. In human blood, Lp-PLA(2) is predominately associated with low-density lipoprotein (LDL). This study examines the ability of lifestyle modification (diet and exercise) and combination lipid therapy to reduce Lp-PLA(2) levels while also determining the relationship between changes in LDL cholesterol and Lp-PLA(2). Thirty dyslipidemic patients who received lifestyle intervention and combination lipid therapy for an average of 6 months were included in these analyses (mean age, 60.9 years); 40% had stable angiographically established coronary artery disease, 40% had the metabolic syndrome, and 70% were men. Drug therapy included omega-3 fish oil, extended-release niacin, colesevelam hydrochloride, and a fixed combination of 10-mg ezetimibe and 40-mg simvastatin. The study revealed a 33% reduction in mean Lp-PLA(2) values (baseline 224.9+/-47.5 vs posttreatment 149.5+/-35.5 ng/mL; P<.001). Significant changes in mean LDL cholesterol from baseline (127.9+/-49.3 vs posttreatment 65.2+/-32.1 mg/dL; P<.001) were also observed. However, regression analysis revealed only a weak positive relationship between changes in LDL cholesterol and Lp-PLA(2)...Continue Reading

References

Aug 1, 1995·Circulation·E FalkV Fuster
Oct 6, 2000·The American Journal of Pathology·F D KolodgieR Virmani
Feb 9, 2002·Arteriosclerosis, Thrombosis, and Vascular Biology·Vasilis TsimihodimosAlexandros D Tselepis
Dec 14, 2002·Journal of the American College of Nutrition·Artemis P Simopoulos
Jun 29, 2005·Atherosclerosis·Michelle A AlbertPaul M Ridker
Oct 7, 2005·Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition·Tricia A BabcockN Joseph Espat
Nov 2, 2006·Current Medical Research and Opinion·Allen J TaylorLance E Sullenberger
Nov 28, 2006·The American Journal of Cardiology·Peter Libby, William Sasiela
Jul 28, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Vasilios G SaougosAlexandros D Tselepis
Sep 11, 2007·Clinical Therapeutics·Michael H DavidsonUNKNOWN COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators

❮ Previous
Next ❯

Citations

Sep 24, 2021·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·E M SamoilovaV P Baklaushev

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.